We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Fresh off the FDA’s March 1 authorization of Johnson & Johnson’s (J&J) single-shot vaccine, President Biden announced that the U.S. has secured an additional 100 million doses of the shot, doubling its original supply agreement with the company. Read More
Amgen has agreed to acquire Five Prime Therapeutics, a South San Francisco biotech company, for $1.9 billion, a deal that will net the biopharma titan a pipeline that includes a promising investigational gastric cancer drug. Read More
Germany’s CureVac has partnered with pharma giant Novartis to potentially manufacture hundreds of millions of doses of the small company’s COVID-19 vaccine candidate, CVnCoV, which is now under review by the European Medicines Agency (EMA). Read More
Perrigo is transforming itself into a “consumer self-care” business, according to Murray Kessler, president and CEO of the Dublin, Ireland-based company. Read More
Ovid Therapeutics is selling the global rights to an investigational drug for rare epileptic diseases to Takeda Pharmaceutical in a deal worth potentially $856 million — as Ovid shifts gears and focuses on research of new neurological therapies. Read More
New Mexico’s attorney general has filed a lawsuit against Gilead Sciences, Teva Pharmaceuticals and Bristol Myers Squibb (BMS) over alleged anticompetitive practices that caused the state to significantly overpay for HIV medications. Read More